| | Reference | Age (years) | Sex | Diagnosis | Karyotype | Confirmatory method |
| | Our case | 69 | M | AML | 46, XY, t(12; 22)(p13; q12) | WGS | | Buijs et al. [10] | 19 | F | AML-M4 | 47, XX, + 8, t(12; 22)(p13; q12) | RT-PCR, sequencing | | Chen et al. [11] | 53 | F | AML-M0 | 47, XY, + 9, t(12; 22)(p13; q12)[9]/46, XY[l] | RT-PCR | | Nakazato et al. [12] | 63 | M | AML-M2 | 46, XY, t(12; 22)(p13; q12)[20] | RT-PCR, sequencing | | Rosenzweig et al. [14] | 3 | M | AML-DS | 47, XY, + 8, + 21c, t(12; 21; 22)(p13; q22; q12) | RNA-Seq | | Shao et al. [15] | 24 | M | AML-M0 | 45, X, − Y, t(12; 22)(p13; q12)[10] | RT-PCR, sequencing | | Shao et al. [15] | 36 | M | AML-M0 | 46, XY, t(12; 22)(p13; q12) [7]/46, XY[3] | NA | | Shao et al. [15] | 62 | F | AML-M4 | 47, XX, + 8, t(12; 22)(p13; q12)[10] | RT-PCR | | Shao et al. [15] | 21 | F | AML-M4 | 48, XX, + 8, t(12; 22)(p13; q12), + 22[20] | RT-PCR, sequencing | | Wang et al. [4] | 46 | M | AML-M5 | 49, XY, + 8, t(12; 22)(p13; q12), + 21, + der(22), t(12; 22) (p13; q13)[20]/50, idem, + 18[1] | RT-PCR | | Wang et al. [4] | 4 | M | AML-M5 | 47, XY, + 8, t(12; 22)(p13; q12)[1]/47, idem, der(1)t(1; 13) (p32; q12), add(2)(p21), add(9)(q13), add(13) (q12)[1]/46, idem, der(1)t(1; 13)(p32; q12), add(2) (p21), − 8, add(9)(q13), add(13)(q12) [18]/46, XY[1] | RT-PCR | | Nofrini et al. [13] | 58 | F | t-AML | 47, XX, del(5)(q13q33), + 21[3]/46, idem, − 7, t(12; 22)(p13; q12)[9] | RT-PCR, sequencing | | Wang et al. [4] | 19 | M | MPAL (T/myeloid) | 47, XY, + 8, t(12; 22)(p13; q12)[14]/46, XY[6] | RT-PCR | | Wang et al. [4] | 11 | M | MPAL (T/myeloid) | 47, X, add(Y)(p11.2), t(4; 7)(q31.3; q36), + 8, t(12; 22) (p13; q12)[17]/47, idem, del(11)(q23)[2]/47, idem, t(10; 13) (p11.2; q14)[1] | RT-PCR | | Wang et al. [4] | 60 | M | CMML | 47, XY, + 8, t(12; 22)(p13; q12), del(20)(q11.2)[20] | RT-PCR | | Shao et al. [15] | 49 | F | CMML | 46, XX, t(12; 22)(p13; q12)[10] | RT-PCR, sequencing | | Buijs et al. [10] | 15 | M | MDS | 46, XY, t(12; 22)(p13; q12) | RT-PCR, sequencing | | Vieira et al. [16] | 63 | F | t-MDS | 46, XX, t(12; 22)(p13; q12)[31]/46, idem, del(20) (q11q13)[9] | RT-PCR | | Buijs et al. [10] | 58 | M | AP-CML | 46, XY, t(12; 22)(p13; q12) | RT-PCR, sequencing |
|
|
M, male; F, female; AML, acute myeloid leukemia; DS, Down syndrome; t-AML, therapy-related acute myeloid leukemia; MPAL, mixed-phenotype acute leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome; t-MDS, therapy-related myelodysplastic syndrome; AP-CML, accelerated-phase chronic myeloid leukemia; WGS, whole-genome sequencing; RT-PCR, real-time polymerase chain reaction; RNA-Seq, RNA sequencing. Age, sex, diagnosis, karyotype, and MN1::ETV6 confirmation method for myeloid neoplasms harboring MN1::ETV6 fusion.
|
